Phase 2 Colorectal Cancer Trial, Recruiting NCT03667170 Sponsor: 3D Medicines (Sichuan) Co., Ltd. Condition: Colorectal Cancer
Back to Colorectal Cancer

Phase 2 Colorectal Cancer Trial, Recruiting

NCT03667170
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with locally advanced or metastatic colorectal cancer, or another type of solid tumour cancer, confirmed through a tissue sample test.
  • People whose tumour has tested positive for a specific genetic feature known as MMR deficiency or MSI-H (a marker related to how cancer cells repair their DNA).
  • People who have at least one tumour that can be measured on a scan.
  • People who are generally active and able to carry out daily activities, with a performance score of 0 or 1 on a standard medical scale (confirm with trial site).
  • People who are expected to live for more than 12 weeks.
  • People whose blood counts and organ function (such as liver and kidneys) are at adequate levels.

Who may not be able to join:

  • People who have taken part in another clinical trial or used an experimental treatment or device within the past 4 weeks, or who have had specific anti-cancer treatment within the past 2 weeks.
  • People who have not yet recovered from significant side effects caused by previous cancer treatments.
  • People who have previously received a type of cancer treatment known as an immune checkpoint therapy.
  • People who have had major surgery within the past 4 weeks.
  • People who have another active or progressing cancer that has required treatment within the past 5 years.
  • People who have active cancer spread to the brain or the lining of the brain or spinal cord.
  • People who have an active autoimmune disease that has required medication to treat.
  • People who have a known history of HIV infection.
  • People who have signs of a lung condition called interstitial lung disease.
  • People who have a known history of significant heart problems.
  • People who are unwilling to use highly effective contraception throughout the study.
  • People who have other serious or uncontrolled medical conditions that the trial doctor believes would make participation unsafe.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 22 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Lin Shen, MD, Peking Universtiy Cancer Hospital

Phone: 86-10-88196340

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
3D Medicines (Sichuan) Co., Ltd.
Registry
ClinicalTrials.gov
Start date
22 August 2018
Est. completion
30 December 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Objective Response Rate (ORR)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov